Committed to revolutionizing healthcare through our pioneering VHH technologies

Cerberus Therapeutics was established by Dr. Novalia Pishesha, Professor Hidde Ploegh, and Professor Harvey Lodish. Our innovative approach harnesses the power of VHHs derived from alpacas. With a focus on autoimmunity and infectious diseases, we aspire to reshape the future of medicine and improve the lives of countless individuals.

The autoimmunity platform targets major histocompatibility complex class II antigens (MHC II), engaging all types of professional antigen-presenting cells such as dendritic cells, macrophages, and B cells. This approach “instructs” and “empowers” the immune system to rewire itself, potentially presenting a cure for immune-mediated diseases.

Cerberus’ infectious disease platform employs engineered VHHs that recognize antibody light chains. These VHHs are combined with small molecule antivirals or pathogen-specific VHHs to create powerful adducts. These adducts are strategically designed to activate the complement system and engage polyclonal antibodies, mounting a robust protective response against the recognized pathogen with vaccinal effects.